Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 9.54 and a fair value of HKD 14.07 [2][19]. Core Insights - The company is expected to achieve a net profit of at least RMB 100 million in 2025, marking its first annual profit after significant losses in previous years [6][7]. - Revenue is projected to grow significantly, with estimates of RMB 784 million in 2025, representing a year-on-year increase of approximately 194% from RMB 266 million in 2024 [14][15]. - The company is accelerating its commercialization capabilities, particularly in its core business areas of intelligent robotics and drug discovery solutions, which are expected to drive revenue growth [7][14]. - The report highlights the company's partnerships with industry leaders, including BASF and JW Pharmaceutical, to deliver AI-driven solutions and develop innovative drugs [8][9]. - The AI pharmaceutical sector is transitioning from early concepts to industrial validation, with 2026 anticipated to be a critical year for validating AI's impact on drug development success rates [12]. Financial Projections - The company’s revenue forecasts for 2025 to 2027 are RMB 784 million, RMB 991 million, and RMB 1.307 billion, respectively, with growth rates of 194%, 26%, and 32% [14][15]. - The EBITDA is expected to turn positive in 2025, with projections of RMB 215 million, followed by RMB 167 million in 2026 and RMB 272 million in 2027 [15]. - The report anticipates a significant reduction in losses, with net profit expected to improve from a loss of RMB 1.517 billion in 2024 to a profit of RMB 114 million in 2025 [6][15]. Business Segments - The intelligent robotics solutions segment is projected to generate revenues of RMB 293 million in 2025, with a year-on-year growth rate of 80% [15]. - The drug discovery solutions segment is expected to see revenues of RMB 491 million in 2025, driven by increased industry penetration and technological advancements [15][18].
晶泰控股（02228）：25年营收高增实现盈利、26年有望迎来行业拐点共识